A new expert consensus calls for individualised prescribing and close monitoring of people with current or past eating disorders as evidence on GLP-1 drugs remains limited.
The rapid rise of GLP-1 medicines such as semaglutide and tirzepatide has changed treatment for type 2 diabetes and obesity, but a new question is now drawing closer attention: what happens when these drugs are used in people with eating disorders, or in those who may be vulnerable to them? According to a recent consensus paper discussed in Psychology Today and published in World Psychiatry, the answer is neither simple optimism nor blanket caution, but a call for careful, individualised prescribing, close follow-up and better evidence.
The paper, developed through a Delphi process involving 45 experts and people with lived experience of eating disorders, says GLP-1 drugs may help some patients, but they also carry risks that clinicians cannot ignore. The strongest point of agreement was that people should be screened for current or past eating disorders before treatment begins. The same consensus work also urges doctors to look beyond body weight alone when deciding whether a prescription is appropriate, particularly in patients with atypical anorexia nervosa or bulimia nervosa marked by strict restriction or significant weight suppression. The National Eating Disorders Association has made similar warnings, arguing that the drugs should be prescribed with caution in people with a history of disordered eating.
Interest in GLP-1 drugs for binge eating disorder remains high because some studies suggest they may reduce binge episodes and related distress. But the evidence base is still thin, and several reviews note that much of it comes from small, uncontrolled or retrospective studies. According to the consensus paper, the best-designed trial so far did not show a significant reduction in binge eating with liraglutide versus placebo, even though weight loss was greater. That distinction matters, because lower body weight does not necessarily mean an eating disorder is improving. Experts say symptoms can appear to ease on the surface while harmful patterns, including rigid rules, intense fear of weight gain and overvaluing shape and size, continue underneath.
That concern is especially important because clinicians are reporting cases in which people with a history of anorexia nervosa have slipped back into severe restriction while taking GLP-1 medicines. Nausea and vomiting, which are common side-effects, can also complicate assessment and may worsen purging behaviour in vulnerable patients. For that reason, the consensus recommendation is for ongoing monitoring of eating-disorder symptoms, food intake, appetite, weight trend, physical stability and quality of life throughout treatment. The paper also says people with eating disorders who are prescribed these drugs should receive evidence-based psychological treatment at the same time, rather than relying on medication alone.
Researchers say the next phase should focus on the questions current studies have left unanswered. The consensus paper calls for long-term data on whether GLP-1 drugs raise, lower or do not change eating-disorder risk, as well as better tools for distinguishing normal appetite suppression from pathological restriction. It also argues that future trials in binge eating disorder should measure more than weight loss and binge frequency, including psychological symptoms, nutritional security, quality of life and what happens when treatment is stopped. With prescriptions for these medicines still climbing, the paper suggests that closer cooperation between obesity specialists and eating-disorder clinicians will be essential.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
